Physician profile
Mansi Kanhere
NPI 1033493267
$790.52
in general payments reported to CMS, 2019-2025
20 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.17 · 2021: $81.64 · 2022: $14.83 · 2023: $202 · 2024: $251 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $145.35 | 2023-2025 | |
| Becton, Dickinson and Company | $124.24 | 2024 | Bard 3dmax Mesh |
| Tolmar, INC. | $108.80 | 2024 | |
| Tandem Diabetes Care, INC. | $79.74 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $44.98 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $34.65 | 2025 | |
| Pfizer INC. | $30.87 | 2020-2023 | |
| Amgen INC. | $30.30 | 2023 | Repatha |
| Insulet Corporation | $27.10 | 2025 | Omnipod |
| Soleno Therapeutics, INC. | $25.21 | 2025 | Vykat Xr |
| Medtronic Minimed, INC. | $22.80 | 2020 | |
| Sequel Med Tech, LLC | $18.57 | 2025 | Twiist |
| Eton Pharmaceuticals, INC. | $15.97 | 2021 | |
| Medtronic, INC. | $15.02 | 2021 | |
| Novo Nordisk INC | $14.85 | 2023 | Sogroya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $14.54 | 2023 | Triptodur |
| Biomarin Pharmaceutical INC. | $13.12 | 2020 | |
| Ascendis Pharma Endocrinology INC | $13.08 | 2023 | |
| Xeris Pharmaceuticals, INC. | $11.33 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansi Kanhere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.